Ocular Therapeutix Shares Are Trading Lower. The Company Announced Topline Results From the Phase 1 HELIOS Study Evaluating AXPAXLI in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Ocular Therapeutix的股價正在走低。該公司公佈了評估中重度至重度非增殖性糖尿病視網膜病變患者AXPAXLI的1期HELIOS研究的主要結果